• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ponatinib both as an effective bridge to allogeneic hematopoietic stem cell transplantation and as posttransplant maintenance therapy in a chronic myeloid leukemia patient with myeloid blast crisis.

作者信息

Küçükyurt Selin, Kelezoğlu Alihan, Elverdi Tuğrul, Özmen Deniz, Ar Muhlis Cem, Eşkazan Ahmet Emre

机构信息

Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.

Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.

出版信息

Hematol Transfus Cell Ther. 2023 Apr-Jun;45(2):275-277. doi: 10.1016/j.htct.2021.04.007. Epub 2021 Jun 16.

DOI:10.1016/j.htct.2021.04.007
PMID:34210618
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10244240/
Abstract
摘要

相似文献

1
Ponatinib both as an effective bridge to allogeneic hematopoietic stem cell transplantation and as posttransplant maintenance therapy in a chronic myeloid leukemia patient with myeloid blast crisis.普纳替尼在一名处于髓系原始细胞危象的慢性髓性白血病患者中，既作为异基因造血干细胞移植的有效桥梁，又作为移植后的维持治疗。
Hematol Transfus Cell Ther. 2023 Apr-Jun;45(2):275-277. doi: 10.1016/j.htct.2021.04.007. Epub 2021 Jun 16.
2
Pre- and post-transplant ponatinib for a patient with acute megakaryoblastic blast phase chronic myeloid leukemia with T315I mutation who underwent allogeneic hematopoietic stem cell transplantation.移植前和移植后ponatinib 治疗伴有 T315I 突变的急性巨核细胞白血病原始细胞危象期的慢性髓性白血病患者，该患者接受了异基因造血干细胞移植。
Int J Hematol. 2019 Jul;110(1):119-123. doi: 10.1007/s12185-019-02628-8. Epub 2019 Mar 16.
3
Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.在伴有T315I突变的费城染色体阳性白血病中，泊那替尼与异基因干细胞移植的总生存期比较。
Cancer. 2017 Aug 1;123(15):2875-2880. doi: 10.1002/cncr.30558. Epub 2017 Apr 7.
4
Salvage and bridging to allogeneic hematopoietic cell transplantation with ponatinib in patients with relapsed or refractory Philadelphia chromosome-positive leukemia.在复发或难治性费城染色体阳性白血病患者中，使用波纳替尼进行挽救治疗并过渡到异基因造血细胞移植。
Int J Hematol. 2019 Feb;109(2):162-168. doi: 10.1007/s12185-018-02571-0. Epub 2018 Dec 3.
5
Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation and/or Conventional Chemotherapy: Report of a Case.波纳替尼作为不适合异基因干细胞移植和/或传统化疗的急变期慢性髓性白血病患者的有效替代策略：1例报告
Case Rep Hematol. 2017;2017:6167345. doi: 10.1155/2017/6167345. Epub 2017 Aug 14.
6
Transplantation from haploidentical donor is not inferior to that from identical sibling donor for patients with chronic myeloid leukemia in blast crisis or chronic phase from blast crisis.对于处于急变期或从急变期进入慢性期的慢性髓性白血病患者，单倍体相合供者移植并不比同卵同胞供者移植差。
Clin Transplant. 2016 Sep;30(9):994-1001. doi: 10.1111/ctr.12779. Epub 2016 Jul 11.
7
Efficacy of ponatinib prior to and after allogeneic hematopoietic stem cell transplantation in an adolescent with chronic myeloid leukemia in blast phase.波纳替尼在一名青少年急变期慢性髓性白血病患者异基因造血干细胞移植前后的疗效
Blood Res. 2021 Dec 31;56(4):342-345. doi: 10.5045/br.2021.2021104.
8
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.使用600毫克伊马替尼治疗的急变期慢性髓性白血病：6年随访后存活患者的结局
Haematologica. 2008 Dec;93(12):1792-6. doi: 10.3324/haematol.13068. Epub 2008 Oct 6.
9
Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia.第三代酪氨酸激酶抑制剂（TKI）帕纳替尼与第二代 TKI 或干细胞移植作为三线治疗慢性期慢性髓性白血病的成本效益比较。
Appl Health Econ Health Policy. 2019 Aug;17(4):555-567. doi: 10.1007/s40258-019-00489-0.
10
Durable molecular response to imatinib mesylate following nonmyeloablative allogeneic stem-cell transplantation for persisting myeloid blast crisis in chronic myeloid leukemia.慢性髓性白血病持续髓系原始细胞危象非清髓性异基因干细胞移植后对甲磺酸伊马替尼的持久分子反应
Haematologica. 2003 Aug;88(8):ECR29.

本文引用的文献

1
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.慢性髓性白血病临床实践指南（2021 年版），NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2020 Oct 1;18(10):1385-1415. doi: 10.6004/jnccn.2020.0047.
2
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.欧洲白血病网络 2020 年治疗慢性髓性白血病的建议。
Leukemia. 2020 Apr;34(4):966-984. doi: 10.1038/s41375-020-0776-2. Epub 2020 Mar 3.
3
Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study.异基因造血干细胞移植治疗慢性粒细胞白血病后维持酪氨酸激酶抑制剂：国际血液和骨髓移植研究中心的一项研究
Biol Blood Marrow Transplant. 2020 Mar;26(3):472-479. doi: 10.1016/j.bbmt.2019.10.017. Epub 2019 Oct 25.
4
Efficacy and safety of low dose ponatinib in a case of Ph-positive acute lymphoblastic leukaemia.低剂量波纳替尼治疗1例Ph阳性急性淋巴细胞白血病的疗效与安全性
Br J Haematol. 2019 Oct;187(1):e15-e17. doi: 10.1111/bjh.16132. Epub 2019 Aug 1.
5
Pre- and post-transplant ponatinib for a patient with acute megakaryoblastic blast phase chronic myeloid leukemia with T315I mutation who underwent allogeneic hematopoietic stem cell transplantation.移植前和移植后ponatinib 治疗伴有 T315I 突变的急性巨核细胞白血病原始细胞危象期的慢性髓性白血病患者，该患者接受了异基因造血干细胞移植。
Int J Hematol. 2019 Jul;110(1):119-123. doi: 10.1007/s12185-019-02628-8. Epub 2019 Mar 16.
6
Clinical characteristics and treatment outcome of patients with isochromosome 17q (i17q) abnormality and myeloid neoplasms: A single center experience.17号染色体等臂染色体（i17q）异常与髓系肿瘤患者的临床特征及治疗结果：单中心经验
Leuk Res Rep. 2018 Jun 20;10:55-56. doi: 10.1016/j.lrr.2018.06.002. eCollection 2018.
7
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.达沙替尼治疗费城染色体阳性白血病的疗效和安全性：2 期 PACE 试验的最终 5 年结果。
Blood. 2018 Jul 26;132(4):393-404. doi: 10.1182/blood-2016-09-739086. Epub 2018 Mar 22.
8
Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.在伴有T315I突变的费城染色体阳性白血病中，泊那替尼与异基因干细胞移植的总生存期比较。
Cancer. 2017 Aug 1;123(15):2875-2880. doi: 10.1002/cncr.30558. Epub 2017 Apr 7.
9
Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?酪氨酸激酶抑制剂用于移植后维持治疗能否改善高危费城染色体阳性白血病患者的预后？
Clin Lymphoma Myeloma Leuk. 2016 Aug;16(8):466-471.e1. doi: 10.1016/j.clml.2016.04.017. Epub 2016 May 5.
10
BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.BCR-ABL 激酶结构域突变，包括马来西亚慢性髓性白血病患者伊马替尼耐药的 2 种新突变——频率和临床结局。
Leuk Res. 2014 Apr;38(4):454-9. doi: 10.1016/j.leukres.2013.12.025. Epub 2014 Jan 6.